Weight Loss + Anti-Aging: Is BIOA the Next Eli Lilly?
In the past five years, $Eli Lilly(LLY)$ stock has skyrocketed more than 736%, driven mainly by its blockbuster type 2 diabetes and weight loss drugs. But the market never runs out of potential big winners, and there’s a new IPO in the biopharma space that might just be the next Lilly.
$BioAge Labs Inc.(BIOA)$ , a biopharma company that recently completed its initial public offering (IPO) and is gearing up to take on the same obesity treatment market as Eli Lilly—plus another massive market: anti-aging drugs.
On September 25th, BioAge raised $238.3 million in its IPO. Before that, the company had raised a total of $321 million from private investors and venture capital firms. And with only $51.5 million in operating expenses over the past 12 months, they’ve got enough cash to fuel their R&D pipeline for a while.
The Game Plan
BioAge is teaming up with competitors Eli Lilly and $NOVO NORDISK B(0QIU.UK)$ to run combination drug trials. Their lead project, azelaprag, is currently in two Phase II trials for an oral obesity treatment. Early evidence shows that this receptor agonist could not only boost the positive effects of other weight-loss meds but also cut down on side effects.
Many people taking Lilly’s Zepbound or Novo’s Wegovy lose muscle mass during treatment, especially older adults. But BioAge claims that azelaprag could help these patients shed weight without sacrificing muscle, improving quality of life. Losing fat while keeping muscle? That’s a huge unmet need in the weight-loss market. If this product hits the market, it could easily become a top player.
And wait—it gets even better.
Azelaprag works by targeting the apelin receptor. BioAge says that activating this receptor mimics some of the physiological effects of exercise, potentially improving physical function and extending both lifespan and healthspan.
Early clinical data shows no major side effects, so it’s not just a potential blockbuster weight-loss drug—it could even replace the gym for older adults, helping them stay healthy without breaking a sweat.
Investment Risks and Outlook
While BioAge is an exciting biotech startup, it’s not generating any revenue yet, and might not for years. They’ll probably have to raise more money by issuing new shares, which could dilute existing shareholders.
Plus, azelaprag still needs to pass clinical trials—if the data disappoints, the stock could tank. Even if it gets approved, there’ll be fierce competition ahead.
That said, anti-aging drugs are poised to become a major player in the biopharma world. Early investors in BioAge might see huge returns from this high-risk, high-reward bet. But if you’re not ready for that kind of risk, there are safer options out there.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
